203 related articles for article (PubMed ID: 32183886)
1. Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients.
Pottecher J; Noll E; Borel M; Audibert G; Gette S; Meyer C; Gaertner E; Legros V; Carapito R; Uring-Lambert B; Sauleau E; Land WG; Bahram S; Meyer A; Geny B; Diemunsch P
Trials; 2020 Mar; 21(1):274. PubMed ID: 32183886
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial.
Desilles JP; Gregoire C; Le Cossec C; Lambert J; Mophawe O; Losser MR; Lambiotte F; Le Tacon S; Cantier M; Engrand N; Trouiller P; Pottecher J
Trials; 2020 Jun; 21(1):548. PubMed ID: 32560746
[TBL] [Abstract][Full Text] [Related]
3. Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19.
Holliday ZM; Earhart AP; Alnijoumi MM; Krvavac A; Allen LH; Schrum AG
Front Immunol; 2021; 12():714833. PubMed ID: 34745093
[TBL] [Abstract][Full Text] [Related]
4. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
Hodson ME
Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
[TBL] [Abstract][Full Text] [Related]
5. Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series.
Weber AG; Chau AS; Egeblad M; Barnes BJ; Janowitz T
Mol Med; 2020 Sep; 26(1):91. PubMed ID: 32993479
[TBL] [Abstract][Full Text] [Related]
6. Dornase alfa for cystic fibrosis.
Yang C; Chilvers M; Montgomery M; Nolan SJ
Cochrane Database Syst Rev; 2016 Apr; 4():CD001127. PubMed ID: 27043279
[TBL] [Abstract][Full Text] [Related]
7. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
McCoy K; Hamilton S; Johnson C
Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
[TBL] [Abstract][Full Text] [Related]
8. Inhaled mannitol for cystic fibrosis.
Nolan SJ; Thornton J; Murray CS; Dwyer T
Cochrane Database Syst Rev; 2015 Oct; (10):CD008649. PubMed ID: 26451533
[TBL] [Abstract][Full Text] [Related]
9. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children.
Riethmueller J; Borth-Bruhns T; Kumpf M; Vonthein R; Wiskirchen J; Stern M; Hofbeck M; Baden W
Pediatr Pulmonol; 2006 Jan; 41(1):61-6. PubMed ID: 16265663
[TBL] [Abstract][Full Text] [Related]
11. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
Fitzgerald DA; Hilton J; Jepson B; Smith L
Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
[TBL] [Abstract][Full Text] [Related]
12. Inhaled Dornase alfa (Pulmozyme) as a noninvasive treatment of atelectasis in mechanically ventilated patients.
Zitter JN; Maldjian P; Brimacombe M; Fennelly KP
J Crit Care; 2013 Apr; 28(2):218.e1-7. PubMed ID: 23266402
[TBL] [Abstract][Full Text] [Related]
13. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.
Bryson HM; Sorkin EM
Drugs; 1994 Dec; 48(6):894-906. PubMed ID: 7533697
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care (the ASPIC trial): study protocol for a randomised controlled trial.
Foucrier A; Roquilly A; Bachelet D; Martin-Loeches I; Bougle A; Timsit JF; Montravers P; Zahar JR; Eloy P; Weiss E;
BMJ Open; 2023 Feb; 13(2):e065293. PubMed ID: 36810173
[TBL] [Abstract][Full Text] [Related]
15. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial.
Mainz JG; Schien C; Schiller I; Schädlich K; Koitschev A; Koitschev C; Riethmüller J; Graepler-Mainka U; Wiedemann B; Beck JF
J Cyst Fibros; 2014 Jul; 13(4):461-70. PubMed ID: 24594542
[TBL] [Abstract][Full Text] [Related]
16. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
[TBL] [Abstract][Full Text] [Related]
17. Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series.
Weber AG; Chau AS; Egeblad M; Barnes BJ; Janowitz T
medRxiv; 2020 May; ():. PubMed ID: 32511514
[TBL] [Abstract][Full Text] [Related]
18. The role of dornase alfa in the treatment of cystic fibrosis.
Cramer GW; Bosso JA
Ann Pharmacother; 1996 Jun; 30(6):656-61. PubMed ID: 8792953
[TBL] [Abstract][Full Text] [Related]
19. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.
Goa KL; Lamb H
Pharmacoeconomics; 1997 Sep; 12(3):409-22. PubMed ID: 10170464
[TBL] [Abstract][Full Text] [Related]
20. Timing of dornase alfa inhalation for cystic fibrosis.
Dentice R; Elkins M
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD007923. PubMed ID: 27457496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
